CNBC Daily Open: Treasury attempts to rein in bond yields as U.S. debt swells past $40 trillion

U.S. Treasury plans to “at least” double purchases of 10–30-year securities from $2B to $4B per operation over the next two months, pushing the 30-year Treasury yield down ~9 bps to ~5.19% (and the 10-year to ~4.64%). The yield drop lifted stocks ~0.2% after a three-day losing streak and boosted risk assets, with bitcoin up >7% and ether up >18%. Separately, the article flags the U.S. deficit at $1.8T YTD and interest costs near $1.2T this year—casting doubt on how much “time” the buybacks can buy—while Trump renews criticism that policy rates are “artificially high” and escalates economic threats against Iran. In company news, Moderna shares rose 177% and Merck gained >12% on promising Phase 3 personalized cancer vaccine results combined with Keytruda.

Analysis

The rate move is a technical bid for duration, not a fix for sovereign risk. Near term it can compress term premium and mechanically support long-duration equities and crypto, but it also signals that financing costs are now constraining policy, which keeps the market hypersensitive to inflation and auction data. If the 10-year holds below the mid-4s for a few weeks, multiple expansion should continue in the highest-duration names; if not, the reversal can be abrupt because this is a flow-driven rally, not a growth re-acceleration.

The oncology data are a bigger strategic issue for MRNA than the headline pop suggests. The market is starting to value platform optionality rather than a single asset, while MRK gets a more durable but slower-burn benefit through franchise extension and patent-cliff deferral. The missing piece is commercial proof: without overall survival and a clear approval timeline, the current enthusiasm is front-loading value that may not appear on the income statement for 12-24 months.

NVDA’s Nordic deal flow reinforces that the bottleneck in AI is shifting from chips to power, permitting, and rack deployment. That helps NVDA preserve pricing power and ecosystem control, but it also means revenue conversion depends on actual capacity coming online, not just demand signals. Separately, a genuine Iran enforcement campaign is a latent inflation tail risk: oil and shipping can reprice within weeks, which would quickly undo the duration rally and pressure rate-sensitive winners.

Key Decisions for Investors

• Buy TLT or IEF on any yield retracement over the next 2-8 weeks; use a 10y yield stop above 4.8% as the falsifier and prefer call spreads if vol is rich.
• Pair long MRK / short MRNA for 1-3 months: MRK is the cleaner way to express any durable oncology franchise extension, while MRNA’s gap looks ahead of regulatory and commercialization proof.
• Keep NVDA as a structural long, but add only on pullbacks; the thesis is ecosystem control plus continued scarcity pricing, with the main risk being delayed rack deployment or a broader risk-off move if yields re-accelerate.
• Set a tactical alert on XLE/USO rather than chase now; if Brent breaks above recent highs on stronger Iran sanctions enforcement, rotate into energy and tanker exposure quickly.